Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Progenics' Double Dose of Good News

More than any other industry, drug development contains the most "what have you done for me lately" investors.

Witness Progenics Pharmaceuticals (Nasdaq: PGNX  ) , which dropped more than 60% when its lead drug, Relistor, failed a phase 3 trial last month for postoperative ileus, a constipation-like condition that follows abdominal surgery.

Then the stock jumped more than 30% in the other direction yesterday after the drug was recommended for approval in the European Union for treating opioid-induced constipation (OIC), and is trading up another 26% today after the FDA approved it last night. In fact Progenics has roughly tripled since I said investors had overreacted to the failed drug study.

Yesterday, Progenics and marketing partner Wyeth (NYSE: WYE  ) received a positive recommendation from the Committee for Medicinal Products for Human Use, which advises the European Medicines Agency on which drugs to approve. Relistor should be approved in a few months and then Wyeth can begin working out pricing with insurance and health-care agencies in the various EU countries. Wyeth expects to begin selling the drug in the U.S. in June.

Wyeth and Progenics will likely have the OIC market all to themselves for a while. The nearest-term competitor, Entereg, from Adolor (Nasdaq: ADLR  ) and GlaxoSmithKline (NYSE: GSK  ) , has enough long-term safety issues to keep it from being approved as a treatment for OIC.

Relistor will be used only after front-line treatments like Novartis' (NYSE: NVS  ) Ex-Lax have already been tried. The market may be relatively small, but for Progenics, which didn't have any approved drugs until now, any sales are better than none.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 630699, ~/Articles/ArticleHandler.aspx, 10/21/2016 4:58:28 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
PGNX $5.54 Down -0.16 -2.81%
Progenics Pharmace… CAPS Rating: ****
ADLR.DL $4.77 Down +0.00 +0.00%
Adolor Corp CAPS Rating: *
GSK $41.13 Down -0.30 -0.72%
GlaxoSmithKline CAPS Rating: ***
NVS $75.54 Down -0.38 -0.50%
Novartis CAPS Rating: ****